Nanologica AB (publ) (NICA.ST)
SEK 0.9
(3.45%)
SEK 0.9
(3.45%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 69.88 Million SEK | -67.99% |
| 2022 | 53.37 Million SEK | 21.44% |
| 2021 | 43.95 Million SEK | 25.22% |
| 2020 | 35.09 Million SEK | 24.13% |
| 2019 | 28.27 Million SEK | 23.89% |
| 2018 | 22.82 Million SEK | -11.41% |
| 2017 | 25.76 Million SEK | 7.28% |
| 2016 | 24.01 Million SEK | 17.57% |
| 2015 | 20.42 Million SEK | 2.03% |
| 2014 | 20.01 Million SEK | 58.3% |
| 2013 | 12.64 Million SEK | 80.58% |
| 2012 | 7 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 4.07 Million SEK | -58.35% |
| 2024 Q2 | 13.44 Million SEK | 159.26% |
| 2023 Q1 | 12.14 Million SEK | -13.1% |
| 2023 Q3 | 9.92 Million SEK | -28.93% |
| 2023 Q2 | 13.95 Million SEK | 14.96% |
| 2023 FY | 17.08 Million SEK | -67.99% |
| 2023 Q4 | 9.78 Million SEK | -1.36% |
| 2022 Q3 | 10.96 Million SEK | -18.97% |
| 2022 Q2 | 13.52 Million SEK | -9.27% |
| 2022 FY | 53.37 Million SEK | 21.44% |
| 2022 Q1 | 14.91 Million SEK | 44.72% |
| 2022 Q4 | 13.97 Million SEK | 27.45% |
| 2021 Q1 | 10.62 Million SEK | 42.41% |
| 2021 FY | 43.95 Million SEK | 25.22% |
| 2021 Q2 | 11.12 Million SEK | 4.68% |
| 2021 Q4 | 10.3 Million SEK | -13.42% |
| 2021 Q3 | 11.9 Million SEK | 7.0% |
| 2020 Q1 | 8.49 Million SEK | 2.33% |
| 2020 FY | 35.09 Million SEK | 24.13% |
| 2020 Q4 | 7.46 Million SEK | -20.15% |
| 2020 Q2 | 9.79 Million SEK | 15.24% |
| 2020 Q3 | 9.34 Million SEK | -4.59% |
| 2019 FY | 28.27 Million SEK | 23.89% |
| 2019 Q3 | 6.37 Million SEK | -18.49% |
| 2019 Q2 | 7.81 Million SEK | 35.66% |
| 2019 Q1 | 5.76 Million SEK | 3.66% |
| 2019 Q4 | 8.3 Million SEK | 30.34% |
| 2018 Q1 | 5.46 Million SEK | -27.43% |
| 2018 Q2 | 6.31 Million SEK | 15.62% |
| 2018 Q3 | 5.49 Million SEK | -13.03% |
| 2018 Q4 | 5.55 Million SEK | 1.23% |
| 2018 FY | 22.82 Million SEK | -11.41% |
| 2017 Q2 | 6.83 Million SEK | -0.68% |
| 2017 FY | 25.76 Million SEK | 7.28% |
| 2017 Q4 | 7.52 Million SEK | 60.35% |
| 2017 Q3 | 4.69 Million SEK | -31.35% |
| 2017 Q1 | 6.88 Million SEK | 9.17% |
| 2016 Q1 | 5.45 Million SEK | -7.41% |
| 2016 FY | 24.01 Million SEK | 17.57% |
| 2016 Q4 | 6.3 Million SEK | 4.35% |
| 2016 Q3 | 6.04 Million SEK | -2.77% |
| 2016 Q2 | 6.21 Million SEK | 13.93% |
| 2015 Q4 | 5.89 Million SEK | 13.8% |
| 2015 Q1 | 3.36 Million SEK | -42.55% |
| 2015 Q2 | 5.05 Million SEK | 50.25% |
| 2015 FY | 20.42 Million SEK | 2.03% |
| 2015 Q3 | 5.17 Million SEK | 2.37% |
| 2014 Q4 | 5.85 Million SEK | 0.0% |
| 2014 Q2 | 4.44 Million SEK | 0.0% |
| 2014 Q1 | 4.44 Million SEK | 0.0% |
| 2014 FY | 20.01 Million SEK | 58.3% |
| 2014 Q3 | 5.85 Million SEK | 31.89% |
| 2013 FY | 12.64 Million SEK | 80.58% |
| 2012 FY | 7 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 95.385% |
| Camurus AB (publ) | 1.05 Billion SEK | 93.405% |
| Mendus AB (publ) | 129.13 Million SEK | 45.882% |
| Lipum AB (publ) | 37.3 Million SEK | -87.329% |
| NextCell Pharma AB | -576.01 Thousand SEK | 12232.76% |
| Simris Alg AB (publ) | 38.64 Million SEK | -80.858% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -146.721% |
| Active Biotech AB (publ) | 44.8 Million SEK | -55.966% |
| Amniotics AB (publ) | 29.07 Million SEK | -140.393% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -376.947% |
| BioArctic AB (publ) | 89.62 Million SEK | 22.025% |
| Cantargia AB (publ) | 290.01 Million SEK | 75.902% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -219.192% |
| CombiGene AB (publ) | 44.14 Million SEK | -58.316% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 51.124% |
| Genovis AB (publ.) | 88.19 Million SEK | 20.76% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 39.267% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -861.571% |
| Intervacc AB (publ) | 79.78 Million SEK | 12.406% |
| Kancera AB (publ) | 63.07 Million SEK | -10.796% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -1166.298% |
| LIDDS AB (publ) | 27.75 Million SEK | -151.827% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -863.427% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 48.579% |
| OncoZenge AB (publ) | 15.9 Million SEK | -339.403% |
| Saniona AB (publ) | 1.07 Million SEK | -6389.044% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 78.263% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 80.458% |
| Xintela AB (publ) | 57.31 Million SEK | -21.933% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 61.544% |
| Ziccum AB (publ) | 27.87 Million SEK | -150.689% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -326.114% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 77.242% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -63.931% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -295.221% |
| Corline Biomedical AB | 30.16 Million SEK | -131.659% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -20.43% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 15.97% |
| Aptahem AB (publ) | 10.01 Million SEK | -597.967% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 48.114% |
| Fluicell AB (publ) | 28.61 Million SEK | -144.215% |
| Biovica International AB (publ) | 133.72 Million SEK | 47.737% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -253.143% |
| AcouSort AB (publ) | 25.87 Million SEK | -170.084% |
| Abliva AB (publ) | 27.86 Million SEK | -150.797% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 63.883% |
| 2cureX AB (publ) | 36.51 Million SEK | -91.377% |
| I-Tech AB | 40.14 Million SEK | -74.073% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 91.868% |
| Cyxone AB (publ) | 28.21 Million SEK | -147.703% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 36.099% |
| Biosergen AB | 26.8 Million SEK | -160.685% |
| SynAct Pharma AB | 224.49 Million SEK | 68.869% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -58.201% |
| BioInvent International AB (publ) | 441.4 Million SEK | 84.167% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -191.752% |
| Alzinova AB (publ) | 36.39 Million SEK | -92.018% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 75.88% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -789.57% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 36.99% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -375.422% |